Investment
Features
FeesSafety
Academy
More
Pluang+

Compare EPAM Systems Inc (EPAM) vs Illumina, Inc. (ILMN) Price & Performance

EPAM Systems IncTrade
Illumina, Inc.Trade

Price performance (Past 24H)

Key statistics

EPAM Systems Inc vs Illumina, Inc. — how do they compare? EPAM Systems Inc trades at $99 (market cap $5.15B), while Illumina, Inc. trades at $193.06 (market cap $29.12B). The key difference: Illumina, Inc. is far larger — about 5.7× EPAM Systems Inc's market cap, and Illumina, Inc. is trading nearer its 52-week high, EPAM Systems Inc nearer its low. Which is the better fit depends on your goals.

EPAMILMN
Market Cap
$5.15B$29.12B
Sector
TechnologyHealth
52-Week High
$221.40$205.10
52-Week Low
$76.04$91.00
Enterprise Value
$4.52B$30.48B

Returns comparison

Trailing returns across standard periods

About EPAM Systems Inc

EPAM Systems Inc provides software product development and digital platform engineering services to clients located around the world. The company services include Software Product Development, Custom Application Development, Application Testing, Enterprise Application Platforms, Application Maintenance, and Support and Infrastructure Management. The company focuses on innovative and scalable software solutions. The company uses industry standard and custom developed technology, tools, and platforms to deliver results to handle business challenges. The company primarily offers its solutions in the following industries: financial services, travel and consumer, software and hi-tech, life sciences and healthcare. The majority of revenue is generated from North American clients.

Read more on EPAM

About Illumina, Inc.

Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.

Read more on ILMN